Zobrazeno 1 - 10
of 61
pro vyhledávání: '"M.S. Aymerich"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rafael Franco, Enric I. Canela, Sergi Ferré, Kjell Fuxe, Gemma Navarro, Carmen Lluis, Josefa Mallol, Daniel Marcellino, Jordi Ortiz, Antoni Cortés, Vicent Casadó, Peter J. McCormick, M.S. Aymerich, Estefanía Moreno
Publikováno v:
Proceedings of the National Academy of Sciences. 107:18676-18681
It is well known that cocaine blocks the dopamine transporter. This mechanism should lead to a general increase in dopaminergic neurotransmission, and yet dopamine D 1 receptors (D 1 Rs) play a more significant role in the behavioral effects of cocai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7809bf4cad324f3a4f47257ea30bb7
https://doi.org/10.1073/pnas.1008911107
https://doi.org/10.1073/pnas.1008911107
Publikováno v:
Current Opinion in Pharmacology. 10:67-72
The adenosine A(2A)-dopamine D(2) receptor heteromer is one of the most studied receptor heteromers. It has important implications for basal ganglia function and pathology. Recent studies using Bioluminescence and Sequential Resonance Energy Transfer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be89746a77d9af2e64e8944d4a5c5642
https://doi.org/10.1016/j.coph.2009.10.002
https://doi.org/10.1016/j.coph.2009.10.002
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 69:844-851
Glial cell-line derived neurotrophic factor (GDNF), a potent neurotrophic factor for dopaminergic neurons, appeared as a promising candidate for treating Parkinson's disease. GDNF microencapsulation could ensure protection against degradation due to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9262721fcd835e17806b2dd227a79bc4
https://doi.org/10.1016/j.ejpb.2008.02.015
https://doi.org/10.1016/j.ejpb.2008.02.015
Publikováno v:
International Journal of Pharmaceutics. 344:9-15
Glial cell line-derived neurotrophic factor (GDNF) neuroprotective effect on dopaminergic neurons has been described in vitro and in vivo, turning up as a promising drug for the treatment of Parkinson's disease. Unglycosylated bacteria-obtained GDNF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50f976d656a860c5d2894f26fbb986d
https://doi.org/10.1016/j.ijpharm.2007.04.003
https://doi.org/10.1016/j.ijpharm.2007.04.003
Autor:
Eduardo Ansorena, Elisa Garbayo, José L. Lanciego, M.S. Aymerich, Claudia N. Montero-Menei, María J. Blanco-Prieto
Publikováno v:
Journal of Controlled Release
Journal of Controlled Release, Elsevier, 2009, 135 (2), pp.119-126. ⟨10.1016/j.jconrel.2008.12.010⟩
Journal of Controlled Release, Elsevier, 2009, 135 (2), pp.119-126. ⟨10.1016/j.jconrel.2008.12.010⟩
International audience; Glial cell line-derived neurotrophic factor (GDNF) has shown promise in the treatment of neurodegenerative disorders of basal ganglia origin such us Parkinson's disease (PD). In this study, we investigated the neurorestorative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6241d85551f6c2fefc6f665cac62e57
https://hal.univ-angers.fr/hal-03171809
https://hal.univ-angers.fr/hal-03171809
Publikováno v:
Anales del Sistema Sanitario de Navarra v.29 n.3 2006
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Dadun. Depósito Académico Digital de la Universidad de Navarra
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Dadun. Depósito Académico Digital de la Universidad de Navarra
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease. Current therapies are symptomatic and, although these therapies are efficacious during the early stages of the disease, they present important side ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae5b0bc1fc6c4e2ee4d92aee8c5713d4
https://doi.org/10.4321/s1137-66272006000500002
https://doi.org/10.4321/s1137-66272006000500002
Autor:
M. Moreno-Igoa, M.S. Aymerich, Tomás González-Hernández, Mónica Pérez-Manso, José L. Lanciego, A. M. Muñoz-Patiño, Pedro Barroso-Chinea
Publikováno v:
The European journal of neuroscience. 23(8)
The position of the caudal intralaminar nuclei within basal ganglia circuitry has largely been neglected in most studies dealing with basal ganglia function. During the past few years, there has been a growing body of evidence suggesting that the tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45d80037d59d5792719d78c5dd0010ec
https://pubmed.ncbi.nlm.nih.gov/16630057
https://pubmed.ncbi.nlm.nih.gov/16630057